Citations

Clear

187 citation(s) found for "Ha, Gavin".

Effect of ATP-sensitive Potassium Channel Openers on Intraocular Pressure in Ocular Hypertensive Animal Models
Chowdhury, Uttio Roy, Millar, J. Cameron , Holman, Bradley H., Anderson, Kjersten J. , Roddy, Gavin W. , Fautsch, Michael P. , Roy Chowdhury, Uttio, Dosa, Peter I.

Mayo Clinic

Investigative Opthalmology & Visual Science | February 7, 2022 | Volume: 63 | Issue: 2 | Pages: 15

10.1167/iovs.63.2.15 | PMID 35129587 Get It

Zanubrutinib for treatment‐naïve and relapsed/refractory chronic lymphocytic leukaemia: long‐term follow‐up of the phase I/II AU‐003 study
Cull, Gavin , Burger, Jan A. , Opat, Stephen , Gottlieb, David , Verner, Emma , Marlton, Paula , Johnston, Patrick, Simpson, David , Prathikanti, Radha, Wu, Kenneth, Novotny, William , Huang, Jane , Tam, Constantine S , Burger, Jan A , Opat, Stephen , Trotman, Judith , Muñoz, Javier , Stern, Jennifer C., Tam, Constantine S.

Mayo Clinic

British Journal of Haematology | December 16, 2021 | Volume: 196 | Issue: 5 | Pages: 1209-1218

10.1111/bjh.17994 | PMID 34915592 Get It

SummaryThe phase I/II AU‐003 study in patients with treatment‐naïve (TN) or relapsed/refractory (R/R) chronic lymphocytic leukaemia/small lymphocytic lymphoma demonstrated that zanubrutinib therapy results in clinically meaningful and durable responses with acceptable safety and tolerability. We report updated safety and efficacy data for 123 patients with a median follow‐up of 47·2 months. Patients received zanubrutinib 160 mg twice daily (81 patients), 320 mg once daily (40), or 160 mg once daily (two). Discontinuations due to adverse events or disease progression were uncommon. The overall response rate (ORR) was 95·9% (TN, 100%; R/R, 95%) with 18·7% achieving complete response (CR). Ongoing response at 3 years was reported in 85·7%. The ORR in patients with del(17p)/tumour protein p53 mutation was 87·5% (CR 16·7%). The 2‐ and 3‐year progression‐free survival estimates were 90% (TN, 90%; R/R, 91%) and 83% (TN, 81%; R/R, 83%) respectively. The most reported Grade ≥3 adverse events were neutropenia (15·4%), pneumonia (9·8%), hypertension (8·9%) and anaemia (6·5%). The annual incidence of atrial fibrillation, major haemorrhage, Grade ≥3 neutropenia and Grade ≥3 infection decreased over time. With a median follow‐up of ~4 years, responses remain clinically meaningful and durable and long‐term tolerability to zanubrutinib therapy continues.
Association of Metabolic Syndrome With Glaucoma and Ocular Hypertension in a Midwest United States Population
Wu, Kristi Y., Hodge, David O. , White, Launia J. , McDonald, Jacinta, Roddy, Gavin W.

Mayo Clinic

Journal of Glaucoma | December 3, 2021 | Volume: 31 | Issue: 6 | Pages: e18-e31

10.1097/ijg.0000000000001968 | PMID 34860182 Get It

Précis: For patients with glaucoma, metabolic syndrome was associated with higher intraocular pressure and greater central corneal thickness. Patients with metabolic syndrome were more likely to have ocular hypertension. Purpose: The purpose of this study was to determine whether glaucomatous optic neuropathy, also known as glaucoma, and ocular hypertension are more likely to occur in patients with metabolic syndrome. Patients and Methods: Patients in Olmsted County, MN, were identified as having metabolic syndrome based on diagnosis codes, laboratory values, and/or medication use to meet 3 or more of the 5 standard criteria for diagnosing metabolic syndrome: systemic hypertension, hyperglycemia, hypertriglyceridemia, reduced high-density lipoprotein cholesterol, and central adiposity defined by increased body mass index. Patients with glaucoma, including primary open angle, low tension, pigment dispersion, and pseudoexfoliation, were identified using diagnostic codes. The charts of patients with glaucoma were individually reviewed to collect visual acuity, intraocular pressure, cup to disc ratio, central corneal thickness, visual field mean deviation, retinal nerve fiber layer thickness, and treatment of intraocular pressure. Patients with ocular hypertension were separately identified and similarly evaluated. Results: For patients with glaucoma, those with metabolic syndrome had higher intraocular pressure and greater central corneal thickness compared with those without metabolic syndrome. After adjustment for central corneal thickness, there was no longer a significant difference in intraocular pressure between groups. Metabolic syndrome was also associated with the diagnosis of ocular hypertension, and although central corneal thickness trended higher in patients with metabolic syndrome, it did not attain statistical significance. Conclusion: In Olmsted County, though metabolic syndrome was associated with ocular hypertension and higher intraocular pressure in patients with glaucoma, the results were likely related to a thicker central corneal in this patient population.
Multiple Systemic Vascular Risk Factors Are Associated With Low-Tension Glaucoma
Funk, Robert O., Hodge, David O. , Kohli, Darrell, Roddy, Gavin W.

Mayo Clinic

Journal of Glaucoma | November 3, 2021 | Volume: 31 | Issue: 1 | Pages: 15-22

10.1097/ijg.0000000000001964 | PMID 34731871 Get It

Précis: Multiple systemic vascular-associated conditions including systemic hypertension and hypotension, diabetes mellitus, migraine headache, peripheral vascular disease, Raynaud syndrome, and anemia were associated with low-tension glaucoma. Purpose: The purpose of this study was to identify systemic risk factors associated with low-tension glaucoma. Patients and Methods: A retrospective case-control study design was employed to identify patients seen at the Mayo Clinic Department of Ophthalmology between 2005 and 2015 with low-tension glaucoma and an age-matched and sex-matched control group, each containing 277 patients. Results: The low-tension glaucoma group had more myopic refractive errors (−1.6 vs. −1.0 D, P <0.001), lower intraocular pressure (14.2 vs. 15.2 mm Hg, P <0.001), and a higher cup-to-disc ratio (0.7 vs. 0.3, P <0.001). The low-tension glaucoma group was significantly less likely to be obese (body mass index >30, P =0.03). This group had a significantly higher prevalence of systemic hypertension [odds ratio (OR): 1.64, P =0.004], diabetes mellitus (OR: 3.01, P <0.001), peripheral vascular disease (OR: 2.61, P =0.009), migraine headache (OR: 2.12, P =0.02), anemia (OR: 2.18, P =0.003), systemic hypotension (OR: 4.43, P <0.001), Raynaud syndrome (OR: 3.09, P =0.05), and angiotensin-converting enzyme inhibitor (OR: 1.64, P =0.01) or calcium channel blocker use (OR: 1.98, P =0.004). After adjusting for systemic hypertension, calcium channel blocker use remained significant (OR: 1.70, P =0.03). No significant difference was found between groups with respect to hyperlipidemia, obstructive sleep apnea, coronary artery disease, carotid stenosis, stroke, or statin, angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, beta-blocker, or metformin use. Conclusions: Multiple vascular-associated conditions were associated with low-tension glaucoma including systemic hypertension, diabetes mellitus, peripheral vascular disease, migraine headache, Raynaud syndrome, anemia, systemic hypotension, and calcium channel blocker use. This study strengthens the evidence for the vascular hypothesis of low-tension glaucoma.
Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement
Bagley, Stephen , Kothari, Shawn, Rahman, Rifaquat , Lee, Eudocia Q. , Dunn, Gavin P. , Galanis, Evanthia , Chang, Susan M. , Nabors, Burt , Ahluwalia, Manmeet S. , Stupp, Roger , Reardon, David A. , Khagi, Simon , Weller, Michael , Wen, Patrick Y. , Nabors, Louis Burt , Mehta, Minesh P , Sulman, Erik P , Weller, Michael , Khasraw, Mustafa , Galanis, Evanthia , Stupp, Roger , Ahluwalia, Manmeet S , Mehta, Minesh P. , Grossman, Stuart A. , Sulman, Erik P. , Sampson, John Howard , Cloughesy, Timothy F. , Wen, Patrick Yung , Khasraw, Mustafa

Mayo Clinic

Clinical Cancer Research | September 24, 2021 | Volume: 28 | Issue: 4 | Pages: 594-602

10.1158/1078-0432.ccr-21-2750 | PMID 34561269 Get It

Abstract Therapeutic advances for glioblastoma have been minimal over the past 2 decades. In light of the multitude of recent phase III trials that have failed to meet their primary endpoints following promising preclinical and early-phase programs, a Society for Neuro-Oncology Think Tank was held in November 2020 to prioritize areas for improvement in the conduct of glioblastoma clinical trials. Here, we review the literature, identify challenges related to clinical trial eligibility criteria and trial design in glioblastoma, and provide recommendations from the Think Tank. In addition, we provide a data-driven context with which to frame this discussion by analyzing key study design features of adult glioblastoma clinical trials listed on ClinicalTrials.gov as “recruiting” or “not yet recruiting” as of February 2021.
Racial diversity and reporting in FDA registration trials for thoracic malignancies from 2006 to 2020.
Chiang, Ryan S. , Glover, Michael , Hui, Gavin , Wakelee, Heather A. , Desai, Aakash , Lythgoe, Mark Peter , Khaki, Ali Raza

Mayo Clinic

Journal of Clinical Oncology | September 21, 2021 | Volume: 39 | Issue: 28_suppl | Pages: 135-135

10.1200/jco.2020.39.28_suppl.135 Get It

135 Background: Black patients have a disproportionately high incidence and mortality from lung cancer. Despite the importance of clinical trials, there continue to be significant racial disparities in recruitment for pivotal registration studies. In 2016, the FDA recommended reporting racial enrollment with a minimum of 5 categories (White, Black, Asian, American Indian or Alaskan Native [AIAN] and Native Hawaiian or Pacific Islander [NHPI]). The International Committee of Medical Journal Editors also recommend reporting race and ethnicity. We evaluated race reporting and representation in registration trials for thoracic cancers. Methods: We reviewed the FDA website and identified all new drug licensing indications in thoracic malignancies (small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC) and mesothelioma) from 2006 to 2020. NSCLC was further classified as EGFR+, ALK+, other mutation and NOS (no driver mutation). Clinical trials cited on the licensing label for market authorization were recorded and the corresponding registration trial publication was identified. If race was unreported or underreported (defined as ≤3 groups) in the licensing study, then additional information was obtained from clinicaltrials.gov. We calculated the proportion of registration trials meeting FDA criteria and the proportion of each racial group in trials. Results: From 2006-2020, we identified 55 new licensing indications, involving 26 unique drugs; 5 approvals in SCLC, 49 approvals in NSCLC and 1 in mesothelioma. Prior to the FDA race reporting guidelines, 33% (6/18) of registration studies did not meet FDA requirements. This improved to 27% (10/37) after the guideline introduction. Overall 29,545 patients participated in thoracic registration trials; 66% White, 22% Asian, 2% Black, <1% AIAN, <1% NHPI, 1% other or multiple races and 9% unknown. Table shows race distribution by cancer subtype. Conclusions: Although improving, a substantial number of registrational clinical trials in thoracic oncology still do not report race per FDA guidance. In addition, Black individuals are disproportionately under-represented in registration trials. Greater efforts are needed for the inclusion of Black patients and other minorities in clinical trials.[Table: see text]
Circulating Cell-Free DNA as Biomarker of Taxane Resistance in Metastatic Castration-Resistant Prostate Cancer
Francini, Edoardo , Ou, Fang‐Shu , Wolfe, Eric, O’Connor, Edward , Gydush, Gregory, Kelleher, Kaitlin M. , Bhatt, Rupal S. , Balk, Steven P. , Sweeney, Christopher J. , Adalsteinsson, Viktor A. , Taplin, Mary‐Ellen , Choudhury, Atish D. , Wolfe, Eric G, Balk, Steven , Choudhury, Atish D , Ou, Fang-Shu , Sweeney, Christopher , Rhoades, Justin , Ha, Gavin

Mayo Clinic

Cancers | August 12, 2021 | Volume: 13 | Issue: 16 | Pages: 4055

10.3390/cancers13164055 | PMID 34439209 Get It

There are no biomarkers predictive of resistance to docetaxel or cabazitaxel validated for patients with metastatic castration-resistant prostate cancer (mCRPC). We assessed the association between ABCB1 amplification and primary resistance to docetaxel or cabazitaxel for patients with mCRPC, using circulating cell-free DNA (cfDNA). Patients with ≥1 plasma sample drawn within 12 months before starting docetaxel (cohort A) or cabazitaxel (cohort B) for mCRPC were identified from the Dana–Farber Cancer Institute IRB approved database. Sparse whole genome sequencing was performed on the selected cfDNA samples and tumor fractions were estimated using the computational tool ichorCNA. We evaluated the association between ABCB1 amplification or other copy number alterations and primary resistance to docetaxel or cabazitaxel. Of the selected 176 patients, 45 samples in cohort A and 21 samples in cohort B had sufficient tumor content. No significant association was found between ABCB1 amplification and primary resistance to docetaxel (p = 0.58; odds ratio (OR) = 1.49) or cabazitaxel (p = 0.97; OR = 1.06). No significant association was found between exploratory biomarkers and primary resistance to docetaxel or cabazitaxel. In this study, ABCB1 amplification did not predict primary resistance to docetaxel or cabazitaxel for mCRPC. Future studies including ABCB1 amplification in a suite of putative biomarkers and a larger cohort may aid in drawing definitive conclusions.
P2T2: Protein Panoramic annoTation Tool for the interpretation of protein coding genetic variants
DeVoe, Elias, Zenka, Roman M. , Blackburn, Patrick R. , Cousin, Margot A. , Boczek, Nicole J. , Kocher, Jean‐Pierre , Klee, Eric W. , Zimmermann, Michael T. , Oliver, Gavin R. , Zenka, Roman, Zimmermann, Michael T , Urrutia, Raúl

Mayo Clinic

JAMIA Open | August 7, 2021 | Volume: 4 | Issue: 3 | Pages: No page available

10.1093/jamiaopen/ooab065 | PMID 34377961 Get It

Abstract Motivation Genomic data are prevalent, leading to frequent encounters with uninterpreted variants or mutations with unknown mechanisms of effect. Researchers must manually aggregate data from multiple sources and across related proteins, mentally translating effects between the genome and proteome, to attempt to understand mechanisms. Materials and methods P2T2 presents diverse data and annotation types in a unified protein-centric view, facilitating the interpretation of coding variants and hypothesis generation. Information from primary sequence, domain, motif, and structural levels are presented and also organized into the first Paralog Annotation Analysis across the human proteome. Results Our tool assists research efforts to interpret genomic variation by aggregating diverse, relevant, and proteome-wide information into a unified interactive web-based interface. Additionally, we provide a REST API enabling automated data queries, or repurposing data for other studies. Conclusion The unified protein-centric interface presented in P2T2 will help researchers interpret novel variants identified through next-generation sequencing. Code and server link available at github.com/GenomicInterpretation/p2t2.
MASiVar: Multisite, multiscanner, and multisubject acquisitions for studying variability in diffusion weighted MRI
Cai, Leon Y. , Kanakaraj, Praitayini , Nath, Vishwesh , Newton, Allen T. , Edmonson, Heidi A. , Luci, Jeffrey J. , Conrad, Benjamin , Price, Gavin R. , Hansen, Colin B. , Kerley, Cailey I. , Ramadass, Karthik , Yeh, Fang‐Cheng , Garyfallidis, Eleftherios , Descoteaux, Maxime , Rheault, François , Conrad, Benjamin N , Landman, Bennett A , Yang, Qi , Kang, Hakmook , Schilling, Kurt G.

Mayo Clinic

Magnetic Resonance in Medicine | July 16, 2021 | Volume: 86 | Issue: 6 | Pages: 3304-3320

10.1002/mrm.28926 | PMID 34270123 Get It

Purpose Diffusion‐weighted imaging allows investigators to identify structural, microstructural, and connectivity‐based differences between subjects, but variability due to session and scanner biases is a challenge. Methods To investigate DWI variability, we present MASiVar, a multisite data set consisting of 319 diffusion scans acquired at 3 T from b = 1000 to 3000 s/mm 2 across 14 healthy adults, 83 healthy children (5 to 8 years), three sites, and four scanners as a publicly available, preprocessed, and de‐identified data set. With the adult data, we demonstrate the capacity of MASiVar to simultaneously quantify the intrasession, intersession, interscanner, and intersubject variability of four common DWI processing approaches: (1) a tensor signal representation, (2) a multi‐compartment neurite orientation dispersion and density model, (3) white‐matter bundle segmentation, and (4) structural connectomics. Respectively, we evaluate region‐wise fractional anisotropy, mean diffusivity, and principal eigenvector; region‐wise CSF volume fraction, intracellular volume fraction, and orientation dispersion index; bundle‐wise shape, volume, fractional anisotropy, and length; and whole connectome correlation and maximized modularity, global efficiency, and characteristic path length. Results We plot the variability in these measures at each level and find that it consistently increases with intrasession to intersession to interscanner to intersubject effects across all processing approaches and that sometimes interscanner variability can approach intersubject variability. Conclusions This study demonstrates the potential of MASiVar to more globally investigate DWI variability across multiple levels and processing approaches simultaneously and suggests harmonization between scanners for multisite analyses should be considered before inference of group differences on subjects.
MR1‐dependent immune surveillance of the skin contributes to pathogenesis and is a photobiological target of UV light therapy in a mouse model of atopic dermatitis
Naidoo, Karmella , Woods, Katherine , Pellefigues, Christophe , Cait, Alissa , O’Sullivan, David , Gell, Katie , Marshall, Andrew J. , Anderson, R. J. , Li, Yanyan , Schmidt, Alfonso , Prasit, Kef, Mayer, Johannes U. , Gestin, Aurélie, Jacobsen, Elizabeth A. , Gasser, Olivier , Jacobsen, Elizabeth A , Hermans, Ian F. , Painter, Gavin F.

Mayo Clinic

Allergy | June 29, 2021 | Volume: 76 | Issue: 10 | Pages: 3155-3170

10.1111/all.14994 | PMID 34185885 Get It

AbstractBackgroundMucosal‐associated invariant T (MAIT) cells are unconventional T cells which recognize microbial metabolites presented by the major histocompatibility complex class I‐related molecule MR1. Although MAIT cells have been shown to reside in human and murine skin, their contribution to atopic dermatitis (AD), an inflammatory skin disease associated with barrier dysfunction and microbial translocation, has not yet been determined.MethodsGenetic deletion of MR1 and topical treatment with inhibitory MR1 ligands, which result in the absence and functional inhibition of MAIT cells, respectively, were used to investigate the role of MR1‐dependent immune surveillance in a MC903‐driven murine model of AD.ResultsThe absence or inhibition of MR1 arrested AD disease progression through the blockade of both eosinophil activation and recruitment of IL‐4‐ and IL‐13‐producing cells. In addition, the therapeutic efficacy of phototherapy against MC903‐driven AD could be increased with prior application of folate, which photodegrades into the inhibitory MR1 ligand 6‐formylpterin.ConclusionWe identified MAIT cells as sentinels and mediators of cutaneous type 2 immunity. Their pathogenic activity can be inhibited by topical application or endogenous generation, via phototherapy, of inhibitory MR1 ligands.